• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

齐多夫定(AZT)负载乙基纤维素微球经口给药后在比格犬体内的评价

In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs.

作者信息

Abu-Izza K, Tambrallo L, Lu D R

机构信息

College of Pharmacy, University of Georgia, Athens 30602, USA.

出版信息

J Pharm Sci. 1997 May;86(5):554-9. doi: 10.1021/js960461b.

DOI:10.1021/js960461b
PMID:9145378
Abstract

The purpose of this study was to evaluate the in vivo performance of sustained-release zidovudine (AZT) microspheres after oral administration in Beagle dogs, and to establish an in vitro-in vivo correlation. Two AZT microsphere formulations as well as AZT powder were administered to four Beagle dogs. Plasma samples were analyzed by HPLC. The plasma concentration-time data was analyzed by both compartmental and noncompartmental pharmacokinetic analyses. Based on the calculated pharmacokinetic parameters, in vivo release profiles were simulated and compared with in vitro release profiles in three different release media. Significantly longer mean residence time (MRT) was observed after administration of the sustained-release microspheres compared with AZT powder. Significantly lower maximum (Cmax) concentration values and longer times to Cmax (tmax) values were also observed. Formulation I showed the longest MRT (4.4 h). AZT plasma concentration was maintained above the minimum effective concentration for approximately 10 h after administration of Formulation I. The relative bioavailability of the microsphere formulations with respect to AZT powder was not significantly different from 1. The in vitro release of the three formulations was slower in simulated gastric fluid compared with simulated intestinal fluid. The addition of enzymes and mucin to the release media significantly lowered the in vitro release rate of AZT from the microspheres formulations, but not from AZT powder. A good level of in vitro-in vivo correlation (Level A correlation) was achieved with a release medium that was composed of simulated gastric fluid with pepsin and mucin for 2 h followed by simulated intestinal fluid with pancreatin and mucin for 8 h. This in vitro model may be used to predict the in vivo release of AZT, in the further development of controlled-release AZT formulations.

摘要

本研究的目的是评估口服给药后齐多夫定(AZT)缓释微球在比格犬体内的性能,并建立体外-体内相关性。将两种AZT微球制剂以及AZT粉末给予四只比格犬。通过高效液相色谱法分析血浆样本。通过房室和非房室药代动力学分析对血浆浓度-时间数据进行分析。基于计算得到的药代动力学参数,模拟体内释放曲线并与三种不同释放介质中的体外释放曲线进行比较。与AZT粉末相比,给予缓释微球后观察到平均驻留时间(MRT)显著延长。还观察到最大(Cmax)浓度值显著降低,达到Cmax的时间(tmax)延长。制剂I显示出最长的MRT(4.4小时)。给予制剂I后,AZT血浆浓度在给药后约10小时内维持在最低有效浓度以上。微球制剂相对于AZT粉末的相对生物利用度与1无显著差异。与模拟肠液相比,三种制剂在模拟胃液中的体外释放较慢。向释放介质中添加酶和粘蛋白显著降低了AZT从微球制剂中的体外释放速率,但未降低从AZT粉末中的释放速率。使用由含有胃蛋白酶和粘蛋白的模拟胃液2小时,随后含有胰酶和粘蛋白的模拟肠液8小时组成的释放介质,实现了良好的体外-体内相关性(A级相关性)。在AZT控释制剂的进一步开发中,该体外模型可用于预测AZT的体内释放。

相似文献

1
In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs.齐多夫定(AZT)负载乙基纤维素微球经口给药后在比格犬体内的评价
J Pharm Sci. 1997 May;86(5):554-9. doi: 10.1021/js960461b.
2
Effect of gastrointestinal protein adsorption on the in vitro release of AZT from ethylcellulose microspheres.胃肠道蛋白吸附对阿昔洛韦从乙基纤维素微球体外释放的影响。 需注意,你原文中的药物名称有误,文本中提及的药物是阿昔洛韦(acyclovir,简称 AZT 一般指齐多夫定,这里按照文本实际描述应是阿昔洛韦),按照正确药物名称翻译后内容为:胃肠道蛋白吸附对阿昔洛韦从乙基纤维素微球体外释放的影响。
Pharm Dev Technol. 1998 Nov;3(4):495-501. doi: 10.3109/10837459809028631.
3
Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs.双氯芬酸钠口服缓释制剂在比格犬体内外的比较评价
Pharmazie. 2009 Oct;64(10):648-52.
4
Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.利用茶碱药代动力学比较胃滞留微球与缓释制剂
J Pharm Pharmacol. 2008 Jun;60(6):693-8. doi: 10.1211/jpp.60.6.0003.
5
Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology.
J Pharm Sci. 1996 Feb;85(2):144-9. doi: 10.1021/js950353+.
6
Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).3'-叠氮基-3'-脱氧胸苷(AZT,齐多夫定)的一种控释前药(mPEG-AZT)的合成、体外和体内释放动力学及抗 HIV 活性。
ChemMedChem. 2010 Nov 8;5(11):1893-8. doi: 10.1002/cmdc.201000352.
7
Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.乳铁蛋白纳米颗粒在大鼠口服给药期间提高齐多夫定的安全性、生物利用度和药代动力学
PLoS One. 2015 Oct 13;10(10):e0140399. doi: 10.1371/journal.pone.0140399. eCollection 2015.
8
Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation.齐多夫定透皮给药系统:体外、离体和体内评价
Biopharm Drug Dispos. 2004 Jan;25(1):9-20. doi: 10.1002/bdd.381.
9
Poly(HEMA-Zidovudine) conjugate: a macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug.聚(HEMA-齐多夫定)缀合物:一种用于改善药物生物制药性质的大分子前药。
Drug Deliv. 2011 May;18(4):272-80. doi: 10.3109/10717544.2010.536272. Epub 2010 Nov 26.
10
Pharmacokinetics of zidovudine following intravenous bolus administration of a novel niosome preparation devoid of cholesterol.静脉推注不含胆固醇的新型脂质体制剂后齐多夫定的药代动力学。
Arzneimittelforschung. 2001 Nov;51(11):924-30. doi: 10.1055/s-0031-1300139.

引用本文的文献

1
Cellulose Aerogels: Synthesis, Applications, and Prospects.纤维素气凝胶:合成、应用与展望
Polymers (Basel). 2018 Jun 6;10(6):623. doi: 10.3390/polym10060623.
2
Submicron Matrices Embedded in a Polymeric Caplet for Extended Intravaginal Delivery of Zidovudine.亚微米基质嵌入聚合物胶囊中用于延长齐多夫定阴道内给药
AAPS J. 2017 Nov;19(6):1745-1759. doi: 10.1208/s12248-017-0130-4. Epub 2017 Aug 4.
3
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.兔体内可生物降解纳米球包裹的口服齐多夫定的药代动力学
Antimicrob Agents Chemother. 1999 Apr;43(4):972-4. doi: 10.1128/AAC.43.4.972.